Join Free
SI Premium
RSS Feeds
E-mail Alerts
Portfolio
Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Alnylam Pharmaceuticals
(NQ:
ALNY
)
276.33
+3.18 (+1.16%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 19, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Alnylam Pharmaceuticals
< Previous
1
2
...
9
10
11
12
13
14
15
16
Next >
12 Health Care Stocks Moving In Monday's Intraday Session
December 27, 2021
Gainers Microbot Medical (NASDAQ:MBOT) stock moved upwards by 47.87% to $8.02 during Monday's regular session. The current volume of 63.6 million shares is 153229.83%...
Via
Benzinga
34 Stocks Moving In Monday's Mid-Day Session
December 27, 2021
Gainers Microbot Medical Inc. (NASDAQ: MBOT) shares jumped 69.6% to $9.19 after the company announced a strategic collaboration with Stryker Corporation to develop the LIBERTY...
Via
Benzinga
BridgeBio Pharma Stock Crashes As Pfizer-Rivaling Heart Drug Flops
December 27, 2021
Patients who received the drug didn't improve in the six-minute walking test.
Via
Investor's Business Daily
FDA Approves Alnylam - Novartis' Leqvio As the First siRNA To Reduce Bad Cholesterol
December 23, 2021
The FDA has approved Alnylam Pharmaceuticals Inc's (NASDAQ: ALNY) Leqvio (inclisiran) to lower low-density lipoprotein cholesterol (LDL-C). Leqvio is...
Via
Benzinga
The Daily Biotech Pulse: Novartis Snags Twin FDA Nods, Novavax Positive Vaccine News Continues, Arcutis Psoriasis Application Accepted For Review
December 23, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Novartis Receives FDA Nods For Arthritis Treatment And Cholesterol Drug...
Via
Benzinga
Alnylam Comments on FDA Approval of Leqvio®, the First siRNA (RNAi Therapeutic) Approved to Reduce LDL-C
December 22, 2021
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam Submits CTA Application for ALN-APP, an Investigational RNAi Therapeutic for the Treatment of Alzheimer’s Disease and Cerebral Amyloid Angiopathy
December 22, 2021
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam Publishes 3rd Annual Patient Access Philosophy Report Demonstrating Steady Access to Approved Therapies as Company Enters New Geographies
December 21, 2021
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
The Daily Biotech Pulse: Aldeyra Sinks On Dry Eye Disease Readout, Sanofi Goes Shopping, Regulatory Setback For Aquestive, Aridis Touts Pan-Coronavirus Antibody Cocktail
December 21, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus CytomX Mid-Phase Study Of ADC In Lung And Head & Neck Cancer Patients...
Via
Benzinga
Alnylam Initiates Phase 2 Study of Lumasiran in Patients with Recurrent Kidney Stone Disease
December 20, 2021
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam Submits CTA Application for ALN-XDH, an Investigational RNAi Therapeutic for the Treatment of Gout
December 20, 2021
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
2 Mid-Cap Biopharma Stocks BofA Securities Recommends For 2022
December 14, 2021
Biotech stocks are risky investments and to make a profit informed decision-making is needed. BofA Securities announced its ...
Via
Benzinga
Alnylam Submits Regulatory Applications to the U.S. Food and Drug Administration and European Medicines Agency to Support Label Expansion for OXLUMO® for the Treatment of Advanced Primary Hyperoxaluria Type 1
December 14, 2021
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
The Week Ahead In Biotech (Dec. 6-Dec. 11): Daré FDA Decision, Adcom Tryst For Reata, Multiple Conference Presentations And More
December 06, 2021
The omicron variant concerns were front and center in the markets in the week ended Dec. 3, and biotech stocks did not escape the brunt of selling in the wake of the negative...
Via
Benzinga
Exposures
Product Safety
Alnylam Ranks #1 in Boston Globe’s Top Places to Work List for 2021
December 02, 2021
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam to Webcast Presentations at Upcoming Investor Conferences
November 23, 2021
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Read Why Analysts Are Going Bullish On This Large-Cap Pharma Stock
November 22, 2021
RBC Capital has upgraded Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) to Outperform from Sector Perform with a price target of $225, up from $144. While M...
Via
Benzinga
How Alnylam Pharmaceuticals Could Take On Pfizer With A 'Catalyst-Rich' 2022
November 22, 2021
Alnylam is working on a drug that could tackle transthyretin cardiomyopathy.
Via
Investor's Business Daily
Expert Ratings For Alnylam Pharmaceuticals
November 22, 2021
Within the last quarter, Alnylam Pharmaceuticals (NASDAQ:ALNY) has observed...
Via
Benzinga
10 Biggest Price Target Changes For Monday
November 22, 2021
MKM Partners cut Activision Blizzard, Inc. (NASDAQ:A...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 22, 2021
November 22, 2021
Upgrades According to Evercore ISI Group, the prior rating for Kimco Realty Corp (NYSE:
Via
Benzinga
Alnylam Announces 2022 Product and Pipeline Goals and Provides Program Updates at R&D Day
November 19, 2021
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Novartis Has $21B From Roche Stake Sale - Which Company Is On Its M&A Radar?
November 18, 2021
Novartis AG (NYSE: NVS) is getting a massive influx of cash from selling its 20-year stake in Roche Holdings AG (OTC: RHHBY), triggering speculation...
Via
Benzinga
Dicerna Stock Rockets On Novo Nordisk's $3.3 Billion Takeover Plan
November 18, 2021
Novo Nordisk is buying an RNA interference company.
Via
Investor's Business Daily
Alnylam Presents New Data for Zilebesiran, an Investigational RNAi Therapeutic for the Treatment of Hypertension, at the American Heart Association Scientific Sessions 2021
November 13, 2021
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam to Webcast Virtual R&D Day
November 12, 2021
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam Initiates KARDIA-2 Phase 2 Study of Investigational Zilebesiran (ALN-AGT) in Patients with Inadequately Controlled Hypertension
November 08, 2021
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam Presents Positive Results from ILLUMINATE-C Phase 3 Study of Lumasiran in Patients with Advanced Primary Hyperoxaluria Type 1
November 05, 2021
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam Named a Science Magazine Top Employer for Third Consecutive Year
November 01, 2021
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Where Alnylam Pharmaceuticals Stands With Analysts
November 01, 2021
Alnylam Pharmaceuticals (NASDAQ:ALNY) has observed the following analyst ra...
Via
Benzinga
< Previous
1
2
...
9
10
11
12
13
14
15
16
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.